Next Article in Journal / Special Issue
A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
Previous Article in Journal
Correlation of Clinicopathological Characteristics of Breast Carcinoma and Depression
Previous Article in Special Issue
Development and Themes of Diagnostic and Treatment Procedures for Secondary Leg Lymphedema in Patients with Gynecologic Cancers
Open AccessFeature PaperReview

Immunotherapy for Uterine Cervical Cancer

Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate 020-8505, Japan
Author to whom correspondence should be addressed.
Healthcare 2019, 7(3), 108;
Received: 28 July 2019 / Revised: 2 September 2019 / Accepted: 10 September 2019 / Published: 17 September 2019
(This article belongs to the Special Issue Diagnosis and Treatment for Gynecologic Cancers)
Cervical cancer is a malignant neoplastic disease that is the fourth most commonly occurring cancer in women worldwide. Since the introduction of angiogenesis inhibitors, treatments for recurrent and advanced cervical cancers have improved significantly in the past five years. However, the median overall survival in advanced cervical cancer is 16.8 months, with a 5-year overall survival rate of 68% for all stages, indicating that the effects of the treatment are still unsatisfactory. The development of a new treatment method is therefore imperative. Recently, in the clinical oncology field, remarkable progress has been made in immunotherapy. Immunotherapy is already established as standard therapy in some fields and in some types of cancers, and its clinical role in all areas, including the gynecology field, will change further based on the outcomes of currently ongoing clinical trials. This manuscript summarizes the results from previous clinical trials in cervical cancer and describes the ongoing clinical trials, as well as future directions. View Full-Text
Keywords: cervical cancer; immunotherapy; immune checkpoint inhibitor cervical cancer; immunotherapy; immune checkpoint inhibitor
MDPI and ACS Style

Kagabu, M.; Nagasawa, T.; Fukagawa, D.; Tomabechi, H.; Sato, S.; Shoji, T.; Baba, T. Immunotherapy for Uterine Cervical Cancer. Healthcare 2019, 7, 108.

AMA Style

Kagabu M, Nagasawa T, Fukagawa D, Tomabechi H, Sato S, Shoji T, Baba T. Immunotherapy for Uterine Cervical Cancer. Healthcare. 2019; 7(3):108.

Chicago/Turabian Style

Kagabu, Masahiro; Nagasawa, Takayuki; Fukagawa, Daisuke; Tomabechi, Hidetoshi; Sato, Saiya; Shoji, Tadahiro; Baba, Tsukasa. 2019. "Immunotherapy for Uterine Cervical Cancer" Healthcare 7, no. 3: 108.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop